论文部分内容阅读
目的分析氨溴特罗口服液用于治疗小儿喘息性疾病的临床疗效。方法收集2011年1月-2012年12月间我院收治的喘息性疾病患儿80例,随机分为观察组和对照组各40例,观察组予以氨溴特罗口服液进行治疗,对照组予以小儿咳喘灵进行治疗,观察两组疗效。结果观察组治疗总有效率为97.5%,高于对照组的87.5%(P<0.05);观察组各项症状消失时间明显较对照组短,且观察组未发现不良反应,对照组不良反应率为7.5%,组间差异明显(P<0.05)。结论氨溴特罗口服液用于治疗小儿喘息性疾病疗效显著,安全可靠,不良反应少,值得推广应用。
Objective To analyze the clinical efficacy of ambroxol oral solution for the treatment of wheezing diseases in children. Methods Eighty children with asthmatic diseases admitted to our hospital from January 2011 to December 2012 were randomly divided into observation group (40 cases) and control group (40 cases). Patients in the observation group were treated with ambroxol orally and the control group Pediatric Kechuanling to be treated, the two groups were observed. Results The total effective rate of the observation group was 97.5%, which was 87.5% higher than that of the control group (P <0.05). The disappearance time of the symptoms in the observation group was shorter than that of the control group, and no adverse reactions were observed in the observation group. The adverse reaction rate Was 7.5%, the difference between groups was significant (P <0.05). Conclusion Ambroxol oral solution for the treatment of asthmatic children with significant efficacy, safety and reliability, fewer adverse reactions, it is worth promoting the application.